OR WAIT 15 SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Best practices for scaling up manufacturing under a short deadline.
Flexible, adaptable processes speed the manufacture of investigational drug products.
Communication and transparency help foster strong manufacturing partnerships.
Innovators, contractors, and technology providers advance cell and gene therapies.
February 22, 2021
The second phase of the Myford facility expansion in California will add upstream and downstream processing suites.
February 18, 2021
The deal expands Wavelength’s drug substance manufacturing footprint and its API CDMO business.
Cascade began production on new facilities to manufacture APIs for clinical and commercial GMP production.
February 17, 2021
The companies have expanded their existing partnership to include 40 Million Doses of COVID-19 vaccine for South Korea.
The acquisition will integrate drug substance, drug product, and clinical testing capabilities under Quotient.
February 04, 2021
The CGMP manufacturing agreement will expand production of lenzilumab, a candidate for COVID-19 therapy, to support a potential emergency use authorization filing.
PathoQuest will apply its experience in viral safety testing and quality control of biologics for mitigating the risk of adventitious agent contamination in biopharmaceutical manufacturing.
February 02, 2021
Accelerated drug development timelines must accommodate all crucial elements of nonclinical safety studies.
Having a clear and detailed understanding of exactly what a biomolecule entails is essential for therapeutics development.
Outsourcing partners can provide a multitude of advantages in the development of drug delivery solutions, including those designed for targeted patient populations.
Collaboration between equipment suppliers and users is leading to innovation and optimization in biopharmaceutical manufacturing.
For drug sponsors that are considering building their own manufacturing facilities, an expert project team is crucial.
CDMOs address the unique challenges of liquid and lyophilized forms as well as preparing for the large capacity needed for COVID-19 vaccines.
February 01, 2021
Nexelis’ recent acquisition of GSK’s Marburg, Germany-based vaccines clinical bioanalytical laboratory expands its bioanalytical capabilities.
The £500,000 (US$686,294)-investment in mass spectrometry support will accelerate biologics development and approval.
Best practices can help ensure supply chain flexibility and viability for biologic drugs in clinical trials.
Contract development and manufacturing organizations provide vital services to rush COVID-19 vaccines to patients.
January 05, 2021
Vendors are finding ways to address the increasingly complex analytical challenges in the biopharmaceutical industry to further biotherapeutic development.
January 03, 2021
Biopharma looks to deliver on COVID-19 vaccines and other promising therapies.
Essential bio/pharma employees show hard work and dedication can pay off for patients.